Analyst Myriam Belghiti of LifeSci Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $53.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myriam Belghiti’s rating is based on Corbus Pharmaceuticals’ strategic positioning and promising development pipeline. The company’s CRB-701 stands out due to its differentiated mechanism and tolerability, which are crucial in its ongoing development for post-platinum and checkpoint-experienced settings. This distinction provides a competitive edge over other treatments, particularly in targeting large, less saturated indications such as head and neck squamous cell carcinoma (HNSCC).
Furthermore, the upcoming dose optimization data for CRB-701 is anticipated to further highlight its advantages over peers, potentially enhancing its value in combination settings. Corbus Pharmaceuticals’ focus on building a tolerability-based case for its assets supports the Buy rating, as it positions the company well for future growth and market penetration.
In another report released on June 2, H.C. Wainwright also maintained a Buy rating on the stock with a $40.00 price target.